Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.35
Bid: 14.00
Ask: 14.90
Change: 0.00 (0.00%)
Spread: 0.90 (6.429%)
Open: 14.35
High: 0.00
Low: 0.00
Prev. Close: 14.35
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of options

8 Nov 2016 18:25

RNS Number : 6778O
Oncimmune Holdings PLC
08 November 2016
 

8 November 2016

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 8 November 2016, options over ordinary shares of the Company were awarded to certain Directors and certain PDMRs under the Company's 2016 Share Option Plan (an amalgamation of the Company's 2005 and 2007 Share Option Plans) as follows.

 

Name

Position

Number of share options awarded

Option exercise price per share (pence)

Percentage of issued share capital (%)

Meinhard Schmidt

Non-executive Chairman

120,370

108

0.236

Geoffrey Hamilton-Fairley

Chief Executive Officer

528,273

1

1.035

119,875

108

0.235

Andrew Millet

Chief Financial Officer

92,593

108

0.181

Andrea Murray

Chief Operational Scientist

41,667

108

0.082

Maarten Brusse

Chief Commercial Officer

74,074

108

0.145

 

The options are subject to the rules of the 2016 Share Option Plan and vest in five equal annual parts, the first fifth vesting on 7 November 2017 and each year thereafter for a further four years, subject to continued employment. Unless otherwise indicated in the table above, the options are exercisable at 108 pence, being the mid-market closing price of the Company's ordinary shares on 7 November 2016

 

For further information:

 

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@oncimmune.co.uk

 

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny, Dominic Wilson

+44 (0) 203 829 5000

 

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

oncimmune@consilium-comms.com

+44 (0) 20 3709 5708

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Meinhard Schmidt

2

Reason for the notification

a)

Position/status

 

Non-Executive Chairman, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

120,370

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

120,370

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Geoffrey Hamilton-Fairley

2

Reason for the notification

a)

Position/status

 

Chief Executive Officer

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

528,273

N/A

119.875

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

648,148

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Andrew Millet

2

Reason for the notification

a)

Position/status

 

Chief Financial Officer

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

92,593

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

92,593

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Andrea Murray

2

Reason for the notification

a)

Position/status

 

Chief Operational Scientist and PDMR

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

41,667

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

41,667

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Maarten Brusse

2

Reason for the notification

a)

Position/status

 

Chief Commercial Officer and PDMR

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

74,074

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

74,074

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBIBDBSDGBGLI
Date   Source Headline
14th Feb 202011:05 amRNSSecond Price Monitoring Extn
14th Feb 202011:00 amRNSPrice Monitoring Extension
12th Feb 20207:00 amRNSHalf Year Report
28th Jan 20207:00 amRNSLung Test More Cost Effective Compared to CT
27th Jan 20207:00 amRNSNotice of Capital Markets Update
23rd Jan 202012:30 pmRNSConsortium of Liver Cancer Industry Leaders
7th Jan 20207:00 amRNSNotice of Half Year Results
7th Jan 20207:00 amRNSChange of Registered Address
12th Dec 20192:07 pmRNSWinner of BioNewsRound Award
29th Nov 20199:58 amRNSResults of Annual General Meeting
4th Nov 20192:46 pmRNSNotice of AGM and Posting of Annual Report
4th Nov 20197:00 amRNSDraw down of second tranche of credit facility
1st Nov 20197:10 amRNSOncimmune and Biodesix seal deal
31st Oct 20197:00 amRNSFinal Results
25th Oct 20197:00 amRNSNotice of Full Year Results ended May 2019
16th Oct 20195:01 pmRNSOncimmune welcomes NHS review of cancer screenings
23rd Sep 20197:00 amRNSKey appointments to further strengthen management
20th Sep 20192:32 pmRNSAppointment of Joint Broker
20th Sep 20197:00 amRNSEUR8.5m Credit Facility Secured
18th Sep 20197:00 amRNSOncimmune to Present at 2019 CBIIC
9th Sep 20197:30 amRNSPositive Results for ECLS Trial Presentation
3rd Sep 201912:00 pmRNSECLS at 2019 World Conference for Lung Cancer
1st Aug 201912:00 pmRNSSolebury Trout European Biotech Investor Day
15th Jul 20197:00 amRNSFurther Expansion in Spain for EarlyCDT Lung
4th Jul 201910:38 amRNSCommercialisation Partnership in Russia
2nd Jul 20197:00 amRNSProactive Investors One2One Investor Forum
28th Jun 20197:00 amRNSCommercialisation Agreement in US with Biodesix
26th Jun 20197:00 amRNSBusiness Update
4th Jun 20197:00 amRNSPositive Results for Early Cancer Detection Test
15th May 20197:00 amRNSRegulatory Approval in Israel for EarlyCDT®-Lung
10th May 20197:00 amRNSInitiation of a Multi-Centre Trial in China
17th Apr 20197:00 amRNSHolding(s) in Company
5th Apr 20197:00 amRNSAgreement for Portugal and Spain
2nd Apr 20197:00 amRNSAppointment of Parag Mallick to Scientific Board
1st Apr 20195:19 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSEarlyCDT®-Lung Registered in Columbia
25th Mar 20197:00 amRNSSpanish Private Hospital to Sell EarlyCDT®-Lung
19th Mar 20197:00 amRNSOncimmune acquires Protagen Diagnostics AG
13th Feb 20197:00 amRNSHalf Year Results
31st Jan 20197:00 amRNSNotice of Half Year Results
24th Jan 20197:00 amRNSGrant of Options and PDMR notification
23rd Jan 20197:00 amRNSOncimmune to host Science Day in London today
14th Jan 20197:00 amRNSOncimmune Science Day
20th Dec 20182:13 pmRNSOncimmune signs US distribution agreement
13th Dec 20187:00 amRNSOncimmune appoints new Scientific Board
6th Dec 20184:34 pmRNSSenior Leadership Team Appointments & Board Change
30th Nov 201810:46 amRNSResult of AGM
28th Nov 20187:10 amRNSDistribution Agreements & Registration Outside EU
5th Nov 20187:00 amRNSAnnual Report and Accounts and AGM Notification
31st Oct 20187:00 amRNSResults for the year ended 31 May 2018

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.